A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck

被引：0
|
作者：
Thomas, Jacob S.
Hsu, Robert
Villaflor, Victoria
Riess, Jonathan
Nieva, Jorge
Krailo, Mark
Gutkind, Silvio
Colevas, Dimitri
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT047
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial
    Oppelt, Peter J.
    Puram, Sidharth V.
    Liu, Jingxia
    Ley, Jessica C.
    Adkins, Douglas
    CANCERS, 2025, 17 (03)
  • [32] KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    Soulieres, D.
    Tahara, M.
    De Castro, G., Jr.
    Psyrri, A.
    Rotllan, N. Baste
    Neupane, P. C.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Roy, A.
    Cheng, J.
    Jin, F.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
    Colevas, A. D.
    Park, J. J.
    Fang, B.
    Shao, J.
    U'Ren, L.
    Odegard, J.
    Lal, I.
    Phan, M.
    Thein, K. Z.
    Adkins, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E42 - E43
  • [34] Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84).
    Fisher, Terrence Lee
    Evans, Elizabeth E.
    Mallow, Crystal L.
    Foster, Amber
    Boise, Megan
    Smith, Ernest
    Leonard, John E.
    Chaney, Marya F.
    Beck, Joseph Thaddeus
    Hager, Steven Jeffrey
    Mekhail, Tarek
    Seetharamu, Nagashree
    Baumgart, Megan
    Saba, Nabil F.
    Steuer, Conor Ernst
    Adkins, Douglas
    Burtness, Barbara
    Zauderer, Maurice
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18033 - E18033
  • [35] Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial
    Honma, Yoshitaka
    Swiecicki, Paul L.
    Rosenberg, Ari Joseph
    Hanna, Glenn J.
    Yang Bruce, Justine
    Fujisawa, Takao
    Muro, Kei
    Kaplan, Jason B.
    Gorla, Seema Rao
    Liu, Shubin
    Meng, Changting
    Geiger, Jessica Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS148 - TPS148
  • [36] Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial
    Swiecicki, Paul
    Rosenberg, Ari J.
    Hanna, Glenn J.
    Bruce, Justine Yang
    Fujisawa, Takao
    Honma, Yoshitaka
    Muro, Kei
    Kaplan, Jason
    Gorla, Seema Rao
    Liu, Shubin
    Meng, Changting
    Geiger, Jessica Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer
    Sheth, Siddharth
    Weiss, Jared
    FUTURE ONCOLOGY, 2018, 14 (16) : 1547 - 1558
  • [38] Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
    Kao, Hsiang-Fong
    Liao, Bin-Chi
    Huang, Yen-Lin
    Huang, Huai-Cheng
    Chen, Chun-Nan
    Chen, Tseng-Cheng
    Hong, Yuan-Jing
    Chan, Ching-Yi
    Chia, Jean-San
    Hong, Ruey-Long
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1560 - 1571
  • [39] A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).
    Sabichi, A. L.
    Kies, M. S.
    Glisson, B. S.
    Lu, C.
    Ginsberg, L. E.
    Bartos, C. I.
    Feng, L.
    Tran, H. T.
    Lippman, S. M.
    Blumenschein, G. R., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Phase II study of paclitaxel, tegafur/uracil and folinic acid as first line treatment in metastatic or recurrent head and neck squamous cell carcinomas.
    Berrocal, A
    Pastor, M
    Caballero, C
    Segura, A
    Garcera, S
    Oltra, A
    Nogueron, E
    Blasco, A
    Lopez, P
    Camps, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 508S - 508S
12345